DCB

Edison issues outlook on Boku (BOKU): Making the complex simple for global merchants

Retrieved on: 
Wednesday, April 10, 2024
DCB, LPM, DCF, Boku, WACC, Growth

EBITDA grew 27% y o y as the company continued to invest in building out its LPM network from a technological and regulatory perspective.

Key Points: 
  • EBITDA grew 27% y o y as the company continued to invest in building out its LPM network from a technological and regulatory perspective.
  • Boku is trading at a small premium to its peer group on FY24/25 EV/EBITDA multiples.
  • In a DCF factoring in meeting the targets by FY27, we estimate the shares could be worth 251p.
  • A growing contribution from Amazon, continued adoption of LPMs and new major merchant sign-ups are the main triggers to achieve this, in our view.

Decubate Token (DCB) Is Now Available for Trading on LBank Exchange

Retrieved on: 
Thursday, March 21, 2024
Ecosystem, Reward, DCB, EVM, Iđoš, Cryptocurrency

Users of LBank Exchange can brace themselves for the DCB/USDT trading pair, which will go live at 12:00 UTC on the slated date.

Key Points: 
  • Users of LBank Exchange can brace themselves for the DCB/USDT trading pair, which will go live at 12:00 UTC on the slated date.
  • As the driving force behind more than 100 successful Web3 businesses, Decubate stands out as a top-tier launchpad and incubator in the world of Web3.
  • LBank Exchange is thrilled to announce the listing of Decubate Token (DCB), standing out as a leading Web3 platform designed to empower entrepreneurs and investors.
  • The DCB token is integral to the functionality of the Decubate platform, granting users access to staking and governance activities.

CONCEPT MEDICAL RECEIVES US FDA IDE APPROVAL FOR MAGICTOUCH AVF INDICATION, THEIR FIFTH US CLINICAL STUDY APPROVAL FOR THE MAGICTOUCH PORTFOLIO

Retrieved on: 
Tuesday, April 2, 2024
Chronic kidney disease, DCB, Kidney disease, Patient, Arteriovenous fistula, IDE, Sirolimus, Quality of life, Trial of the century, Fistula, Clinical trial, Kidney, AVF, PMA, US FDA, Safety, Food, FDA, Health, Pharmaceutical industry

Concept Medical a leader in innovative medical device technology, has announced approval of an Investigational Device Exemption (IDE) for its US FDA Breakthrough designated MagicTouch AVF for the treatment of stenotic lesions of Arteriovenous Fistula (AVF) in the Haemodialysis management of Chronic Renal Failure.

Key Points: 
  • Concept Medical a leader in innovative medical device technology, has announced approval of an Investigational Device Exemption (IDE) for its US FDA Breakthrough designated MagicTouch AVF for the treatment of stenotic lesions of Arteriovenous Fistula (AVF) in the Haemodialysis management of Chronic Renal Failure.
  • The Company has been granted four other US FDA IDE approvals for its MagicTouch product portfolio for different indications.
  • This US FDA IDE approval allows Concept Medical to conduct pivotal clinical studies to gather safety and efficacy data for the MagicTouch Sirolimus Coated Balloon in A.V.
  • With a focus on advancing patient care through innovation, Concept Medical remains dedicated to improving patients' lives worldwide.

CONCEPT MEDICAL RECEIVES US FDA IDE APPROVAL FOR MAGICTOUCH AVF INDICATION, THEIR FIFTH US CLINICAL STUDY APPROVAL FOR THE MAGICTOUCH PORTFOLIO

Retrieved on: 
Tuesday, April 2, 2024
Chronic kidney disease, DCB, Kidney disease, Patient, Arteriovenous fistula, IDE, Sirolimus, Quality of life, Trial of the century, Fistula, Clinical trial, Kidney, AVF, PMA, US FDA, Safety, Food, FDA, Health, Pharmaceutical industry

Concept Medical a leader in innovative medical device technology, has announced approval of an Investigational Device Exemption (IDE) for its US FDA Breakthrough designated MagicTouch AVF for the treatment of stenotic lesions of Arteriovenous Fistula (AVF) in the Haemodialysis management of Chronic Renal Failure.

Key Points: 
  • Concept Medical a leader in innovative medical device technology, has announced approval of an Investigational Device Exemption (IDE) for its US FDA Breakthrough designated MagicTouch AVF for the treatment of stenotic lesions of Arteriovenous Fistula (AVF) in the Haemodialysis management of Chronic Renal Failure.
  • The Company has been granted four other US FDA IDE approvals for its MagicTouch product portfolio for different indications.
  • This US FDA IDE approval allows Concept Medical to conduct pivotal clinical studies to gather safety and efficacy data for the MagicTouch Sirolimus Coated Balloon in A.V.
  • With a focus on advancing patient care through innovation, Concept Medical remains dedicated to improving patients' lives worldwide.

Boston Scientific Receives FDA Approval for the AGENT™ Drug-Coated Balloon

Retrieved on: 
Friday, March 1, 2024
Boston Scientific, Diabetes, Obstruction, DCB, Interventional cardiology, Physician, FDA, ISR, Quality of life, Food, Restenosis, Find, BSX, IDE, Plaque, Radiation, Risk, Food and Drug Administration, Patient, TLF, Coronary artery disease, Pharmaceutical industry

MARLBOROUGH, Mass., March 1, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Drug Administration (FDA) approval for the AGENT™ Drug-Coated Balloon (DCB), which is indicated to treat coronary in-stent restenosis (ISR) in patients with coronary artery disease. ISR is the obstruction or narrowing of a stented vessel by plaque or scar tissue.

Key Points: 
  • First coronary drug-coated balloon in U.S. provides safe, effective alternative to treat coronary in-stent restenosis and reduce risk of reoccurrence
    MARLBOROUGH, Mass., March 1, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Drug Administration (FDA) approval for the AGENT™ Drug-Coated Balloon (DCB), which is indicated to treat coronary in-stent restenosis (ISR) in patients with coronary artery disease.
  • ISR is the obstruction or narrowing of a stented vessel by plaque or scar tissue.
  • Experience the full interactive Multichannel News Release here: https://www.multivu.com/players/English/9029352-boston-scientific-fda-ap...
    "With more than 100,000 patients treated globally to date in both clinical and commercial settings, we are very pleased to introduce this proven therapy as the first drug-coated coronary balloon in the U.S," said Lance Bates, president, Interventional Cardiology Therapies, Boston Scientific.
  • Boston Scientific plans to launch the technology in the U.S. in the coming months.

Boku Welcomes New CEO Stuart Neal After Momentous 2023

Retrieved on: 
Thursday, January 18, 2024
Technology, Payments, Finance, Security, Fintech, Electronic Commerce, Professional Services, Digital Cash Management, Digital Assets, Networks, LON, Virgin Media, Inc., Multimedia, Amazon, Microsoft, Meta, Freedom, Netflix, Vocalink, Barclaycard, Sky, Acquisition, Tencent, IPO, Twilio, Direct carrier billing, GSK plc, DCB, Growth, Online shopping

Neal takes the helm from Jon Prideaux, who announced his intention to retire in July 2023, and will remain on the Board as a Non-Executive Director.

Key Points: 
  • Neal takes the helm from Jon Prideaux, who announced his intention to retire in July 2023, and will remain on the Board as a Non-Executive Director.
  • Boku CEO Stuart Neal brings more than 20 years of payments, banking and innovation leadership experience to Boku, combined with a deep understanding of the Boku business.
  • Neal re-joined Boku as CEO Designate in July 2023 after Jon Prideaux announced his plans to retire.
  • “I am excited to return to Boku as CEO at such a dynamic and promising time for the payments industry,” commented Stuart Neal, CEO, Boku.

TPAY to enable Mobile Payments for PUBG MOBILE in Egypt!

Retrieved on: 
Tuesday, January 16, 2024
PUBG Mobile, UC, Partnership, Survival, MENA, DWB, MEA, Frost, PUBG, Direct carrier billing, Projection, DCB, RC, Growth, Video game

DUBAI, United Arab Emirates, Jan. 16, 2024 (GLOBE NEWSWIRE) -- TPAY MOBILE, META’s most reliable digital micropayments facilitator, today announces, through its partnership with Tencent, the launch of Direct Carrier Billing for PUBG MOBILE in Egypt.

Key Points: 
  • This launch provides gamers in Egypt to easily purchase PUBG MOBILE UC (unknown cash) through the official PUBG shop ‘ Midasbuy ’ and the UC they purchased is promptly added to their PUBG account.
  • Thanks to our partnership, TPAY also enabled DCB payment for other Tencent games in UAE, Oman & Qatar.
  • Tencent first partnered with TPAY Turkey (Payguru) in May 2019 to avail in-game purchases for PUBG through DCB across all of Turkey’s 3 operators.
  • Following this successful partnership, an expansion to offer DCB in MEA, via TPAY's network connections, took place covering PUBG Mobile and other new games.

Reflow Medical Receives CE Mark for Bare Temporary Spur Stent System for Treating de novo or Restenotic Below-the-Knee (BTK) Lesions

Retrieved on: 
Tuesday, January 16, 2024
Surgery, Medical Devices, Health, Health Technology, Cardiology, Mortality, Patient, European, Spur, Principal, MD, MDR, Multimedia, Bare, CLTI, RST, Risk, BTK, Quality of life, De novo, Division, Safety, Medicine, Amputation, CE marking, Medical University of Graz, DCB, Wound healing, Cardiovascular disease, Trial of the century, Physician, Pharmaceutical industry

Reflow Medical, Inc., a developer of innovative medical devices focused on cardiovascular disease, announces it has received CE (Conformité Européenne) Mark certification in the European Union for the Bare Temporary Spur Stent System .

Key Points: 
  • Reflow Medical, Inc., a developer of innovative medical devices focused on cardiovascular disease, announces it has received CE (Conformité Européenne) Mark certification in the European Union for the Bare Temporary Spur Stent System .
  • The device is intended to treat de novo or restenotic lesions in the infrapopliteal arteries with a commercially available drug-coated balloon (DCB) to enhance drug absorption.
  • View the full release here: https://www.businesswire.com/news/home/20240116803175/en/
    The Bare Temporary Spur Stent System is a unique clinical solution known as Retrievable Stent Therapy, or RST.
  • The Bare Temporary Spur Stent System is a unique clinical solution intended to provide stent-like results while leaving no metal behind.

Seismic Therapeutic Closes $121 Million Series B Financing to Advance Immunology Pipeline Optimized by its Machine Learning Platform

Retrieved on: 
Monday, December 4, 2023
Biotechnology, Pharmaceutical, Health, GC, Lightspeed Venture Partners, IND, Seismology, Patient, Investment, Machine learning, GV, Series, Venture round, PD-1, IMPACT, MBA, Doctor of Philosophy, Bidirectional, DCB, Growth, Fc receptor, Polaris Partners, Drug development, Pharmaceutical industry

Seismic Therapeutic, Inc ., the machine learning immunology company, today announced that it has closed a $121 million Series B financing.

Key Points: 
  • Seismic Therapeutic, Inc ., the machine learning immunology company, today announced that it has closed a $121 million Series B financing.
  • In addition, the Series B will enable the continued growth of the company’s pipeline in both the IgSc and DcB product areas, beyond the lead programs.
  • This progress resulted from Seismic’s integration of leading-edge machine learning into drug development in a specific area – biologics for immunology – powered by a diverse team of drug developers and machine learning innovators.
  • “This financing enables us to continue our momentum and advance both of our exciting lead programs into the clinic.

Surmodics Announces TRANSCEND Trial 36-Month Data Presented at 50th Annual VEITH Symposium

Retrieved on: 
Thursday, November 16, 2023
Cardiology, Biotechnology, Other Health, Health, General Health, Other Science, Medical Devices, Research, Hospitals, Science, Clinical Trials, Paclitaxel, TLA, Safety, PAD, Clinical trial, Patient, DCB, Thrombosis, Death, Freedom, Popliteal artery, Pharmaceutical industry, Czech Republic

Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that 36-month data from its TRANSCEND clinical trial was presented by Dr. Peter A. Schneider at the 50th Annual VEITH Symposium in New York, New York.

Key Points: 
  • Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that 36-month data from its TRANSCEND clinical trial was presented by Dr. Peter A. Schneider at the 50th Annual VEITH Symposium in New York, New York.
  • The TRANSCEND trial is a prospective, multi-center, single-blind, randomized, controlled trial to assess the safety and efficacy of the SurVeil™ drug coated balloon (DCB) versus the IN.PACT® Admiral® DCB for treatment of superficial femoral and proximal popliteal artery lesions.
  • The primary efficacy endpoint is 12-month primary patency, defined as freedom from binary restenosis or clinically driven target lesion revascularization (CD-TLR).
  • “The TRANSCEND 36-Month data continues to demonstrate safe and effective performance of the SurVeil DCB.